Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Radiation in Metastatic NSCLC
NCT02221739Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Jul 2014
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in non-small cell lung cancer (NSCLC), sponsored by NYU Langone Health. Primary endpoints: Therapeutic Efficacy (Abscopal Response) and Safety. Started Jul 2014; status: completed.
02
Drugs
ipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02221739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221739.